Starting from fl-benzoylpropionic acid we synthesized 3-(aminomethyl)tetralones in which the amino substituent was d(N-piperaziny1)-p-fluorobutyrophenone (14), 4benzoylpiperidine (15),4-hydroxy-4phenylpiperidine (16) or d(o-methoxypheny1)piperazine (17). The poesible dopamine antagonist activity of theae compounds was investigated in both 'in vitro" and 'in vivo" experiments. These compounds potently inhibited [3H]spiperone binding to D2 striatal receptors and moderately inhibited [3H]SCH-23390 binding to D1 striatal receptors (Kis in the nanomolar and micromolar ranges, respectively). Apomorphine-induced stereotypies and amphetamine group toxicity were antagonized, to different extents, by the compounds under study, with a potency similar to that of haloperidol. Interestingly, no catalepsy was observed after administration of the new compounds (2-8 mgfkg) . The most active compounds 'in vivo" 14 and 15 poseeaeed two butymphenone pharmacophorea. However, the tetralone moiety appeared not critical for their antidopaminergic activity, since all target compounds were less active than haloperidol. These studies provide a pharmacological basis for future research on these new compounds devoid of ataleptogenic activity.
Introduction
Since the discovery of chlorpromazine as an effective antipsychotic agent, large numbers of potential neurolep tics have been synthesized. Despite this intense research activity, there are still relatively few structurally distinct classes of drugs with clinically confirmed antipsychotic activity. The butyrophenones, whose prototype is haloperidol (l),l are perhaps the most important such group.
5, where the Ra represent simple amine substituents.
These compounds are semirigid variants of the general neuroleptic structure Ar-C,-N. We have also studied the a-blocking and antidopaminergic activity of compounds 5 in isolated rat vas deferens, finding that pA2 values increase with the size of the amine moiety? These results have prompted us to synthesize derivatives 14-17 and to investigate their potential antidopaminergic activity.
Interestingly 
Results and Discussion
Chemistry. The general synthetic strategy followed in preparation of these compounds is shown in Scheme I.
Arylbutyrolactones 7a,b were prepared by a method previously described for the unsubstituted compound,B hydroxymethylation of the 8-aroylpropionic acids followed by lactonization to aroylbutyrolactones 6a,b and subsequent reduction of the carbonyl group. Reaction of 7a,b with hydrogen bromide in acetic acid afforded unstable bromo acids 8a,b, which upon ring closure with polyphosphoric acid were converted to 3-(bromomethyl)-ltetralones 18a,b, whose structures were established by ' H NMR. In the nucleophilic reactions with amines, compound 18s invariably gave the elimination product 34-benzobicyclo[4.4.0]heptan-2-one (19a) instead of the desired substituted derivative. the tosylate of 3-(hydroxymethyl)-l-tetralone, was confirmed by analytical and spectral data.
Several attempts were made to block the carbonyl group of (bromomethy1)tetralones 18. It was not possible to obtain the ethylene ketals, and though the ethylene dithioketals 20 were obtained by standard procedures in 70% yield, subsequent attempts at nucleophilic substitution were unsuccessful. In the end, the final products 14-17 (Table 11) were obtained in good yields by substitution with methyl esters 9 and subsequent cyclization of the resulting amino esters 10-13 with PPA (Table I) . was investigated "in vivo" by studying their antagonism of (+)-amphetamine group toxicity and apomorphine-induced stereotyped behavior and catalepsy in mice and "in vitro" by studying ligand binding and their effects on dopamine-and norepinephrine-induced contractions of isolated rat vas deferens. Blockade of (+)-amphetamine lethality in aggregated mice (group toxicity) is a recognized measure of neuroleptic a~tivity.~'-~~ In this study compounds 14b and 15 afforded greatest protection against group toxicity, though with ED,'s greater than that of haloperidol (Table 111 ).
In the antagonism to apomorphine the activity of compound 15 was at all times postadministration (p.a.) similar to just slightly less than that of haloperidol. None of the compounds studied induced catalepsy at dosages in the range 2-8 mg/kg i.p. (data not shown), and since at this dosage level they failed to protect against eserine (data not shown), this absence of cataleptogenic activity cannot have been due to concomitant anticholinergic activity. Their effects in these assays designed to test activity in the striatum (the catalepsy test and possibly the antistereotyping test) are nevertheless somewhat contradictory when considered in the light of previous studies, for while their lack of cataleptogenic activity suggests that they do not block striatal dopaminergic receptors, whose blockade by neuroleptics has been reported to cause catalepsy in experimental animalsmt21 and extrapyramidal symptoms in man,22 their antagonism of apomorphine suggests that they may, the induction of stereotyped activity by apomorphine having been related by several authors to the striatal dopaminergic This possible contradiction would be resolved either if the dopaminergic mesolimbic system as well as the nigrostriatal pathway were involved in the induction of stereotyped behavior by apomorphine (indeed, McKenzie= claimed that only the nucleus accumbens was involved in this response) or if the tetralone dosages used in this study, though sufficient to antagonize apomorphine, were insufficient to elicit a cataleptic response. Whether or not higher tetralone dosages would be cataleptogenic, the existence of a dosage range for which their neuroleptic effects are not associated with catalepsy in mice suggests that it might be possible to use them in man as selective antipsychotics lacking extrapyramidal side effects ( Figure  1) . Antidopaminergic activity was also investigated by measuring the inhibition of dopamineinduced contractions of isolated rat vas deferens which may be mediated by postsynaptic D2 or cyreceptor
The fact that for every antagonist (haloperidol or the new compounds) the pA2 values for norepinephrine and dopamine were practically the same (a result also reported for haloperidol by Leedham and PennefatherFl though not by Simon and Van Maanen32) strongly suggests that both agonists bind to the same receptors in rat vas deferens. Since for haloperidol the pA2 values are unchanged under experimental conditions blocking 8-adrenoceptors (by addition of propranolol), reuptake of catecholamines by neutrons (by addition of cocaine), and extraneuronal uptake (by addition of 8-estradiol)F3 it seems likely that norepinephrine and dopamine both bind to the al-receptors to which norepinephrine is already30 known to bind in this tissue. The pharmacological activity of the new compounds in rat vas deferens would thus consist in adrenergic blocking activity; the hypothesis that the therapeutic effects of antipsychotic drugs are mediated largely through noradrenergic blockade has been reassessed, and several lines of evidence now suggest that antagonism of al-noradrenergic receptors may contribute to the thera-peutic effects of antipsychotic drugsa (Table IV) .
The antipsychotic activity of neuroleptics correlates well with their ability to block D2 receptors,ss but not with Dl blockade? the performance of neuroleptics in behavioral testa is accordingly generally attributed solely to their D2-blocking ability,98 though research carried out since the discovery of selective D1 agonist and suggests that D1 receptors too may mediate the effects of neuroleptics on behavior, and possibly their clinical effect also.-This may explain the differences between the relative potencies of the compounds studied in the ' in vivo" and binding experiments; compound 17, the most D2 selective, was the least effective "in vivo*, indicating the possible contribution of both D1 and D2 receptors to the antipsychotic activity.
In conclusion, all the tetralones tested in this study proved to posseas antipsychotic activity at dosages at which no cataleptic effects were observed. The most active were compounds 14b and 15, both of which have two butyrophenone pharmacophores, one the semirigid (aminomethylltetralone moiety and the other a flexible linear butyrophenone moiety (14b) or a semirigid benzoylpiperidine fragment (15). However, since all the new compounds were less active than haloperidol, their tetralone moiety may not be essential for their neuroleptic activity.
Experimental Section
Chemistry. Melting points were determined with a Kofler hot-stage instrument and with a Gallemkamp capillary melting point apparatus and are uncorrected. Proton magnetic resonance spectra were obtained with a Varian FT-80 (80 MHz) or a Bruker WM-250 (250 MHz) with tetramethylsilane as an internal standard. Infrared spectra were recorded with a Perkin-Elmer 297 spectrometer. Mass spectra were obtained with a Varian MAT-711 (70 eV) apparatus. Elemental analysea were performed in a Perkin-Elmer 240 apparatus at the Micronalyses Service of the University of Santiago de Compostela (Spain), and values are within 0.4% of the theoretical compositions.
4-(N-Piperazinyl)-p-fluorobutyrophenone (22). Method
A. To a solution of 12.87 g (149 mmol) of anhydrous piperazine in 75 mL of methyl isobutyl ketone was added 5.0 g (25 mmol) of w-chloro-p-fluorobutyrophenone dropwise. The solution was refluxed for 12 h. The solvent was removed under reduced pressure, the solid residue was treated with 10% HCl, and the resulting acidic solution was washed with ethyl acetate, made alkaline with aqueous sodium hydroxide solution, and extracted with methylene chloride. The organic extract was washed with water and dried (Na#OJ and the solvent was removed ' in vacuo" to yield 5.38 g (86%) of 22 as an oil which solidified on standing. C-6, CHzCO), 2.58-2.56 (m, 4 H, piperazino (2-3 and C5), 247-242
Method B. To a aolution of 2.10 g (24 mmol) of anhydrous piperazine in 7 mL of methyl isobutyl ketone was added 1.0 g (4 mmol) of 4-chloro-1,l-(ethylenedioxy) -1-(4-fluorophenyl) butane in 3 mL of methyl isobutyl ketone dropwise. The solution was refluxed for 12 h. The solvent was removed under reduced pressure and the residue was dissolved in CHzClz, washed with water to neutral pH, and dried (NazS04). The solvent was removed to leave 1.1 g (92%) of 4-piperazinyl-l,l-(ethylenedioxy)-l-(4-fluorophenyl)butane, which was used for the following reaction without further purification. A solution of 1.1 g (3.4 mmol) of the ethylene ketal and concentrated HC1 (2 mL) in methanol (30 mL) was refluxed for 2 h. The methanol was removed under reduced pressure and the residue was dissolved in water, made alkaline with aqueous ammonia, and extraded with CH2C12. The organic layer was washed with water and dried (NaaO,). The solvent was removed by evaporation under reduced pressure to yield 0.77 g (83%) of 22.
8-(Bromomethy1)-y-phenylbutyric Acid, Methyl Ester (9a).
To a stirred solution of 11.05 g (0.062 mol) of 7 in 17 mL of glacial acetic acid at 0 "C was added 20 mL of 33% HBPAcOH dropwise. After 15 min at room temperature, the solution was heated at 80 "C for 4 h. After cooling, the reaction mixture was poured into ice-water and extracted with chloroform. The chloroform solution was washed several times with water and dried (Na$04) , and the solvent evaporated to afford 15.16 g (94%) of 8.
Methyl ester 9a (R = H) was obtained as usual using 
3-(Bromomethyl)-l-tetralone (18a).
To 196.5 g of well-stirred polyphosphoric acid at 60 "C was slowly added 13.10 g (0.05 mol) of crude 8a, after which the temperature was increased to 120 "C. After 2 h, the reaction mixture was poured into ice-water and extracted with ether. The organic extracts were washed several times with water and dried (NazS04), and the solvent evaporated ' in vacuo". The oily residue was distilled (bp 146 "C, 0.5 mmHg) to yield the desired product, which solidified i"e- 
8-(Aminoethyl)-y-phenylbutyric Acids, Methyl Esters
(10-13). General Pmdures: Method A. To a solution of the appropriate amine (1.9 m o l ) in anhydrous benzene (3 mL) was added B(bromoethy1)-r-phenylbutyric acid methyl ester (0.95 mmol), in anhydrous benzene (1 mL). After 14 h of refluxing the resulting precipitate was removed by filtration and discarded, and the solvent was removed from the fitrate under reduced pressure. The resulting oil was dieeolved in ether and treated with a solution of HC1 in ether to precipitate the salt, which was collected by filtration and recrystallized (Table I ).
Method B. To a solution of the appropriate amine (8.4 "01)
in methyl isobutyl ketone (80 mL) were added anhydrous Na&Os (2.96 g) and KI (0.046 g) followed by B-(bromomethyl)-yphenylbutyric acid methyl ester (8.4 mmol) in methyl isobutyl ketone. This mixture was refluxed for 20 h. Inorganic salts were filtered, and the solvent was removed under reduced pressure. The resulting oil was dieeolved in chloroform, washed several times with water, and dried (Na804). The chloroform was removed under reduced pressure to afford the desired aminomethyl ester (Table I ). Anal.: C, H, N. (14) (15) (16) (17) . General Procedure. To the appropriate aminomethyl ester was slowly added (3.6 "01) 32 g of well-stirred polyphosphoric acid at 90 OC and the temperature was raieed to 130 OC. After 5 h the reaction mixture was poured into ice-water and stirred to obtain a total solution, which was then made alkaline with 5 N NaOH and extracted with C12CH1. The organic phase was washed several times with water to neutral pH and dried (NafiO,), and the Cl,CH2 was removed "in vacuo" to afford the desired 3-(aminomethyl)-l-tetralone (Table 11 ). Anal.: C, H, N.
3-(Aminomethyl)-l-tetralonm
'H NMR (CDClJ data for 146: 6 8. 3 H, 1 H, 2 H, 2 H, 19 H), 2 H, CHzCH2CO) . lab (aromatic lH): 6 8. 3 H, 4 H, 3 H, [2] [3] [4] [5] [6] [7] [8] 1 H, 2 H, 2 H, 6 H, aliphatic), 6 H, (CH&N), 4 H, piperidino, ). 1 6 6 8. 04-8.01 (m, 1 H, C-8), 7.48-7.19 (m, 8 H, aromatic), 3.16-2.29 (m, 15 H, aliphatic) . 1 7 6 8. 1 H, 1 H, 2 H, 4 H), 3.86 (8, 3 H, 15 H, aliphatic) .
Pharmacology. "In Vivo" Experiments. These experiments were peformed in a thennostated room (22 f 1 OC) with a 12/12 h light/dark cycle (8.00-20.00). All were carried out at the same time of day in order to avoid variations caused by circadian rhythms. Male albino mice (Charlee River CD.1) weighing 26 3 g were used throughout. Doses of test compounds, haloperidol, apomorphine, (+)-amphetamine, and eserine were prepared immediately before administration.
In the group toxicity antagonism test, the new compounds or haloperidol (0.25,0.5, 1, and 2 mg/kg) were injected ip 30 min prior to (+)-amphetamine (dose 15 mg/kp ip) in volumes of 0.01 mL/body weight; control groups were administered an equal volume of vehicle. After the first administration, the mice were placed into groups of 10 in circular cages 20 cm in diameter, without food or water; the death rate 24 h after administration of (+)-amphetamine was recorded. Group toxicity antagonism is expressed as EDm (mg/kg), which was calculated as per Litchfield and Wilcoxon.'B Catalepsy was tested in five-mice groups 30 and 60 min after administration of saline solution, haloperidol, or one of the compounds under investigation (six groups for each substance). The mice were placed with their forepaws on one horizontal wire and their hindpaws on another 6 cm away and 2 cm lower; those remaining in this position for over 30 s were considered cataleptic.
In the teat of antagonism to apomorphine-induced stereotyped behavior six-mice groups were treated with 1 mg/kg (sc) of apomorphine 30 min after administration of 2 mg/kg (ip) of the compounds, haloperidol, or saline solution, and during the following l/? h stereotypes were scored every 10 min with the following scale: 0, absence of stereotypes; 1, some stereotyped movement shown; 2, intense smelling, with mastication and licking periods, and 3, large periods of mastication and licking, usually with mice climbing on the wall of the cage."
To test ability to protect against a lethal dose of eserine (2 mg/kg ip), groups of 10 mice were treated ip 30 min before eserine injection, with vehicle, atropine (4 mg/ kg), haloperidol, or the new compounds (2-8 mg/kg). The mice were placed in individual cages and the dead were counted 24 h after injection of eserine.
Vas Deferens Assays. Male SpragueDawley rata (25&300 g) were killed by a blow on the head. The vas deferens was diseected free from adhering tissue, removed, and suspended in a 10-mL tissue bath containing Krebs solution (composition in m M NaCl, 118; KCl, 4.7; MgS04.7H20, 1.2; CaC12.2H20, 2.5; KH2P04, 1.2; NaHCOS, 25; g l u m , 11) maintained at 37 O C and gassed with a mixture of 95% 0 2 and 5% COD After an equil- (46) (-)-Norepinephrine bitartrate and 3-hydroxytyramine hydrochloride were obtained from stock solutions (10 mM) in distilled water containing sodium bisulfite (1%) and kept frozen . Solutions of haloperidol and the test compounds were prepared in distilled water immediately before use. The chemicals used for the preparation of the Krebs solution were of analytical grade.
Binding Assays. Male Wistar rats weighing 250-300 g were killed by cervical dislocation and decapitation. Both striata were quickly dissected on a cold plate, weighed, and stored at -20 "C until assayed.
For determination of [SH]spiperone binding to membrane preparations, tissue was homogenized with a Polytron (setting 6 for 5 s) in 50 vol of ice-cold 50 mM Tris HC1 (pH 7.4) and centrifuged at 4oooOg for 10 min in a Sorvall centrifuge at 4 OC. The pellet was resuspended and the process repeated. The final pellet was resuspended in 200 vol of 50 mM Tris HCl buffer containing 120 mM NaCl. Aliquota (200 pL) of the final BUSpension were incubated with 25 pL of displacing agent or ita vehicle and 25 pL of a solution of [%] spiperone. For equilibrium saturation analysis, six ligand concentration from 0.05 to 1 nM were used. Nonspecific binding was defined by addition of 1od M of (+)-sulphide. For determinations of the ICw values of drugs to displace [Wlspiperone (0.25 nM) binding at least six ascending concentrations of each drug were included in the assay ( 1~-1 0 4 M). All samples were examined in triplicate at each ligand or displacing drug concentration. Samples were incubated for 10 min at 37 OC. The reaction was terminated by rapid vacuum filtration through Whatman GF/C filters, which were washed with 3 x 5 mL of cold buffer.
For the determination of [%]SCH-23390 binding to membrane preparations, paired striata were homogenized in 200 vol of 50 mM Tris HC1 buffer and centrifuged at l OOOg for 10 min, and the supernatant was centrifuged at 2oooOg for 10 min. The pellet was resuspended and the process repeated. The final pellet was resuspended in 50 mM Tris HCl containii 120 mM NaCl, 5 mM KC1, 2 mM CaCl,, and 1 mM MgCl2. Saturation curves were constructed with six ligand concentrations from 0.15 to 2.5 mM. dpm sample -dpm nonspecific binding dpm total binding -dpm nonspecific binding x 100
